Loading…
Thor Medical signed a strategic master supply agreement with ARTBIO for a 5-year supply of Thorium-228, with potential revenues of up to NOK 400 million (USD 38 million). The Thorium-228 will be produced at Thor Medical's planned commercial facility at Herøya Industrial Park in Norway, with an investment decision expected in Q1 2025.
Nordic Nanovector ASA and Thor Medical AS entered into a definitive share exchange agreement for an all-share transaction. The combined company will focus on radionuclide production for cancer treatment, with Scatec Innovation becoming the largest shareholder.